Home > Products > Product Pipeline > Rich Pipeline

Rich Product Pipeline

ActoGeniX’s R&D activities are focused on advancing its broad and diverse pipeline of ActoBiotics™ for the treatment of a variety of severe diseases with high and unmet medical need.

TopAct™ is a versatile and efficient drug discovery platform. ActoGeniX researchers have created a collection of more than 50 different  ActoBiotics™ over the last few years. Choosing the most promising products, ActoGeniX has developed a rich pipeline, comprising products at clinical, preclinical and discovery stage.

 

<Click to enlarge>

 

AG011, the lead product for treatment of Crohn’s disease and ulcerative colitis, has been successfully tested in a Phase 1 clinical trial with Crohn’s disease patients. Importantly, the results from this trial have already provided a first positive indication for efficacy, confirming the promising potential of AG011. ActoGeniX is now conducting a Phase 2 clinical trial, which is expected to be finalized in the course of 2009.

AG013, for the treatment of oral mucositis, is in advanced preclinical development. Initiation of clinical development is planned for early 2009.

Other programs, for which ActoGeniX and its collaborators have already obtained positive initial efficacy data in preclinical models, include celiac disease, autoimmune diseases (e.g., Type 1 diabetes), Type 2 diabetes and allergic diseases.